Looyenga et al. demonstrated that STAT3 is constitutively activated in human NSCLC samples and in a variety of NSCLC lines independent of activating KRAS, EGFR and PDGFR mutations or MET amplification. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.